Close
Smartlab Europe
Achema middle east

Shuwen Biotech Receives CE Mark for EGFR Mutation PCR Kit for Lung Cancer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...
- Advertisement -

Shuwen Biotech announced that it has received CE-IVD marking for its EGFR real time PCR detection kit allowing the company to market its kit in countries that recognize the designation.

The CE Marked kit showcases Shuwen’s strengthening research and development capabilities which ultimately have led to a series of increasingly innovative products for the market. The EGFR kit has a limit of mutation detection at 0.1% in a background of wild-type DNA for key mutations. The kit contains lyophilized reagents which withstand at least 12 freeze/thaw cycles, increasing the kit’s stability while lowering logistics costs for clients.

In addition to the EGFR real time PCR detection kit, Shuwen is leveraging its proprietary CODAR-PCR technology on real-time PCR platform to finalize development of a number of other innovative diagnostics such as EGFR-T790M (liquid biopsy), BRAF, ALK, and ROS1 mutation detection assays. Initial tests show that the EGFR-T790M mutation detection assay has a limit of mutation detection at an exceptional 0.01% in a background of wild-type DNA which holds significant value to various clinical and drug development strategies worldwide.

“At Shuwen, we believe innovation is fundamental to leading the market into new frontiers and this is what we primarily focus on,” said Jay Z. Zhang, CEO of Shuwen Biotech. “Through cutting-edge technical innovations we aim to raise the bar with regards to sensitivity, specificity, convenience of use and transport in molecular diagnostic kits.”

About Shuwen Biotech
Led by U.S. and European diagnostic industry veterans, Shuwen Biotech is engaged in licensing, developing, marketing and distributing innovative products and services for disease diagnosis and personalized medicine. The company strives to provide doctors and their patients with a comprehensive menu of the most innovative products and services for improved disease prediction, screening, diagnosis, prognosis and treatment in the areas of cancer, maternal fetal medicine, acute care, and preventive testing.

Contact
Dr. Vafa Amirkia
bd@shuwendx.cn

Latest stories

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »